SQUAWK/NEWS
Account
Account
Menu
Live News EQUITY FLASH M impact

AGMB Designs NOV-ERA Study

Agomab announces design of NOV-ERA Phase 2b study with Ontunisertib in Fibrostenosing Crohn's Disease

AGMB

This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.